Epstein-Barr virus latent genes

Experimental and Molecular Medicine

Volumn 47, Issue 1, 2015, Pages

  Kang, Myung Soo ^a,b   Kieff, Elliott ^c  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS ANTIGEN 3A; EPSTEIN BARR VIRUS ANTIGEN 3B; EPSTEIN BARR VIRUS ANTIGEN 3C; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2A; LATENT MEMBRANE PROTEIN 2B; MICRORNA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS RNA; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; EPSTEIN BARR VIRUS ANTIGEN; MATRIX PROTEIN; PROTEIN BINDING;

ANTIBODY TITER; ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER GROWTH; CELL TRANSFORMATION; CHROMOSOME; DNA REPAIR; EPITHELIUM CELL; EPSTEIN BARR VIRUS INFECTION; EPSTEIN BARR VIRUS LATENT GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; HUMAN; IMMUNE RESPONSE; LATENT VIRUS INFECTION; LYMPHOBLASTOID CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; COMPLICATION; EPSTEIN BARR VIRUS; GENETICS; METABOLISM; NEOPLASMS; PHYSIOLOGY; VIROLOGY; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; MICRORNAS; NEOPLASMS; PROTEIN BINDING; RNA, VIRAL; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

EID: 84928018253     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2014.84     Document Type: Review

References (336)

1. Epstein M, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;1:702-703.
2. Henle G, Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 1966;91:1248-1256.
3. Henle G, Henle W. Observations on childhood infections with the Epstein-Barr virus. J Infect Dis 1970;121:303-310.
4. Henle G, Henle W, Clifford P, Diehl V, Kafuko GW, Kirya BG et al. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst 1969;43:1147-1157.
5. Henle W, Henle G. The relation of the Epstein-Barr virus to Burkitt's lymphoma. Zentralbl Bakteriol (Orig A) 1972;220:40-46.
6. Henle W, Henle G. Epstein-Barr virus-related serology in Hodgkin's disease. Natl Cancer Inst Monogr 1973;36:79-84.
7. Henle W, Henle G. Evidence for an oncogenic potential of the Epstein-Barr virus. Cancer Res 1973;33:1419-1423.
8. Henle W, Henle G. The Epstein-Barr virus (EBV) in Burkitt's lymphoma and nasopharyngeal carcinoma. Ann Clin Lab Sci 1974;4:109-114.
9. Henle W, Henle G. Epstein-Barr virus and human malignancies. Cancer 1974;34(Suppl):1368-1374.
10. Henle W, Henle G. The sero-epidemiology of Epstein-Barr virus. Adv Pathobiol 1976;5:5-17.
11. Henle W, Henle G. Evidence for an etiologic relation of the Epstein-Barr virus to human malignancies. Laryngoscope 1977;87:467-473.
12. Geser A, de The G, Lenoir G, Day NE, Williams EH. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int J Cancer 1982;29:397-400.
13. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985;36:545-547.
14. Sixbey JW, Vesterinen EH, Nedrud JG, Raab-Traub N, Walton LA, Pagano JS. Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 1983;306:480-483.
15. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984;310:1225-1230.
16. Sixbey JW, Lemon SM, Pagano JS. A second site for Epstein-Barr virus shedding: the uterine cervix. Lancet 1986;2:1122-1124.
17. Sixbey JW, Shirley P, Sloas M, Raab-Traub N, Israele V. A transformationincompetent, nuclear antigen 2-deleted Epstein-Barr virus associated with replicative infection. J Infect Dis 1991;163:1008-1015.
18. Gan YJ, Chodosh J, Morgan A, Sixbey JW. Epithelial cell polarization is a determinant in the infectious outcome of immunoglobulin A-mediated entry by Epstein-Barr virus. J Virol 1997;71:519-526.
19. Pegtel DM, Middeldorp J, Thorley-Lawson DA. Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers. J Virol 2004;78:12613-12624.
20. Young LS, Clark D, Sixbey JW, Rickinson AB. Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet 1986;1:240-242.
21. Young LS, Lau R, Rowe M, Niedobitek G, Packham G, Shanahan F et al. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol 1991;65:2868-2874.
22. Cruchley AT, De Souza YG, Williams DM, Greenspan D, Greenspan JS. Bromodeoxyuridine incorporation and Ki 67 expression in oral hairy leukoplakia. Oral Dis 1998;4:9-15.
23. Walling DM, Clark NM, Markovitz DM, Frank TS, Braun DK, Eisenberg E et al. Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia. J Infect Dis 1995;171:1122-1130.
24. Webster-Cyriaque J, Middeldorp J, Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol 2000;74:7610-7618.
25. Walling DM, Ling PD, Gordadze AV, Montes-Walters M, Flaitz CM, Nichols CM. Expression of Epstein-Barr virus latent genes in oral epithelium: determinants of the pathogenesis of oral hairy leukoplakia. J Infect Dis 2004;190:396-399.
26. Walling DM, Ray AJ, Nichols JE, Flaitz CM, Nichols CM. Epstein-Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation. J Virol 2007;81:7249-7268.
27. Adams A, Lindahl T. Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells. Proc Natl Acad Sci USA 1975;72:1477-1481.
28. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol 1997;182:151-159.
29. Niedobitek G, Kremmer E, Herbst H, Whitehead L, Dawson CW, Niedobitek E et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 1997;90:1664-1672.
30. Niedobitek G, Agathanggelou A, Steven N, Young LS. Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells. Mol Pathol 2000;53:37-42.
31. Kurth J, Hansmann ML, Rajewsky K, Kuppers R. Epstein-Barr virusinfected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc Natl Acad Sci USA 2003;100:4730-4735.
32. Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci USA 2005;102:18093-18098.
33. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005;79:1296-1307.
34. Wang H, Nicholas MW, Conway KL, Sen P, Diz R, Tisch RM et al. EBV latent membrane protein 2A induces autoreactive B cell activation and TLR hypersensitivity. J Immunol 2006;177:2793-2802.
35. Geser A, Lenoir GM, Anvret M, Bornkamm G, Klein G, Williams EH et al. Epstein-Barr virus markers in a series of Burkitt's lymphomas from the West Nile District, Uganda. Eur J Cancer Clin Oncol 1983;19:1393-1404.
36. Henle W, Diehl V, Kohn G, Zur Hausen H, Henle G. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 1967;157:1064-1065.
37. Pope J. Establishment of cell lines from peripheral leukocytes in infectious mononucleosis. Nature 1967;216:810-811.
38. Pope JH, Horne MK, Scott W. Transformation of huiman foetal leukocytes in vitro by filtrates of a human leukaemic line containing herpes-like virus. Int J Cancer 1968;3:857-866.
39. Alfieri C, Birkenbach M, Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 1991;181:595-608.
40. Cohen JI, Wang F, Kieff E. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 1991;65:2545-2554.
41. Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 1989;86:9558-9562.
42. Mannick JB, Cohen JI, Birkenbach M, Marchini A, Kieff E. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 1991;65:6826-6837.
43. Longnecker R, Miller CL, Miao XQ, Tomkinson B, Kieff E. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J Virol 1993;67:2006-2013.
44. Longnecker R, Miller CL, Tomkinson B, Miao XQ, Kieff E. Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol 1993;67:5068-5074.
45. Marchini A, Tomkinson B, Cohen JI, Kieff E. BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J Virol 1991;65:5991-6000.
46. Robertson ES, Grossman S, Johannsen E, Miller C, Lin J, Tomkinson B et al. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol 1995;69:3108-3116.
47. Robertson ES, Tomkinson B, Kieff E. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro. J Virol 1994;68:1449-1458.
48. Swaminathan S, Tomkinson B, Kieff E. Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci USA 1991;88:1546-1550.
49. Tomkinson B, Kieff E. Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 1992;66:2893-2903.
50. Tomkinson B, Robertson E, Kieff E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 1993;67:2014-2025.
51. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993;90:9150-9154.
52. Kaye KM, Izumi KM, Li H, Johannsen E, Davidson D, Longnecker R et al. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation. J Virol 1999;73:10525-10530.
53. Kaye KM, Izumi KM, Mosialos G, Kieff E. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 1995;69:675-683.
54. Izumi KM, Cahir McFarland ED, Riley EA, Rizzo D, Chen Y, Kieff E. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation. J Virol 1999;73:9908-9916.
55. Izumi KM, Cahir McFarland ED, Ting AT, Riley EA, Seed B, Kieff ED. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptorinteracting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol 1999;19:5759-5767.
56. Izumi KM, Kaye KM, Kieff ED. Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation. J Virol 1994;68:4369-4376.
57. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 1997;94:1447-1452.
58. Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptorassociated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 1997;94:12592-12597.
59. Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency IIIinfected cells. J Virol 2004;78:4108-4119.
60. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 2000;97:6055-6060.
61. Teramoto N, Maeda A, Kobayashi K, Hayashi K, Oka T, Takahashi K et al. Epstein-Barr virus infection to Epstein-Barr virus-negative nasopharyngeal carcinoma cell line TW03 enhances its tumorigenicity. Lab Invest 2000;80:303-312.
62. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 1995;2:155-166.
63. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998;9:405-411.
64. Caldwell RG, Brown RC, Longnecker R. Epstein-Barr virus LMP2Ainduced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 2000;74:1101-1113.
65. Swart R, Ruf IK, Sample J, Longnecker R. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-kinase/Akt pathway. J Virol 2000;74:10838-10845.
66. Engels N, Merchant M, Pappu R, Chan AC, Longnecker R, Wienands J. Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module. J Exp Med 2001;194:255-264.
67. Fukuda M, Longnecker R. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt pathway. J Virol 2007;81:9299-9306.
68. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995;333:693-698.
69. Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 1996;70:8653-8659.
70. Miller WE, Mosialos G, Kieff E, Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol 1997;71:586-594.
71. Scholle F, Bendt KM, Raab-Traub N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 2000;74:10681-10689.
72. Morrison JA, Klingelhutz AJ, Raab-Traub N. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol 2003;77:12276-12284.
73. Everly Jr DN, Mainou BA, Raab-Traub N. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol 2004;78:13470-13478.
74. Morrison JA, Raab-Traub N. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol 2005;79:2375-2382.
75. Thornburg NJ, Raab-Traub N. Induction of EGFR expression by EBV LMP1 CTAR1 is mediated by NF-{kappa}B p50 homodimer/BCL-3 complexes. J Virol 2007;81:12954-12961.
76. Komano J, Takada K. Role of bcl-2 in Epstein-Barr virus-induced malignant conversion of Burkitt's lymphoma cell line Akata. J Virol 2001;75:1561-1564.
77. Maruo S, Nanbo A, Takada K. Replacement of the Epstein-Barr virus plasmid with the EBER plasmid in Burkitt's lymphoma cells. J Virol 2001;75:9977-9982.
78. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J 2002;21:954-965.
79. Ruf IK, Rhyne PW, Yang C, Cleveland JL, Sample JT. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol 2000;74:10223-10228.
80. Reisman D, Yates J, Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol 1985;5:1822-1832.
81. Sugden B, Marsh K, Yates J. A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol Cell Biol 1985;5:410-413.
82. Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984;81:3806-3810.
83. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985;313:812-815.
84. Malik-Soni N, Frappier L. Nucleophosmin contributes to the transcriptional activation function of the Epstein-Barr virus EBNA1 protein. J Virol 2014;88:2323-2326.
85. Liu CD, Chen YL, Min YL, Zhao B, Cheng CP, Kang MS et al. The nuclear chaperone nucleophosmin escorts an Epstein-Barr virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells. PLoS Pathogen 2012;8:e1003084.
86. Sivachandran N, Wang X, Frappier L. Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection. J Virol 2012;86:6146-6158.
87. Mansouri S, Pan Q, Blencowe BJ, Claycomb JM, Frappier L. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. J Virol 2014;88:11166-11177.
88. Sivachandran N, Sarkari F, Frappier L. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathogen 2008;4:e1000170.
89. Canaan A, Haviv I, Urban AE, Schulz VP, Hartman S, Zhang Z et al. EBNA1 regulates cellular gene expression by binding cellular promoters. Proc Natl Acad Sci USA 2009;106:22421-22426.
90. Dresang LR, Vereide DT, Sugden B. Identifying sites bound by Epstein-Barr virus nuclear antigen 1 (EBNA1) in the human genome: defining a position-weighted matrix to predict sites bound by EBNA1 in viral genomes. J Virol 2009;83:2930-2940.
91. Sugden B, Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 1989;63:2644-2649.
92. Wood VH, O'Neil JD, Wei W, Stewart SE, Dawson CW, Young LS. Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. Oncogene 2007;26:4135-4147.
93. Flavell JR, Baumforth KR, Wood VH, Davies GL, Wei W, Reynolds GM et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 2008;111:292-301.
94. Baumforth KR, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008;173:195-204.
95. Valentine R, Dawson CW, Hu C, Shah KM, Owen TJ, Date KL et al. Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol Cancer 2010;9:1.
96. O'Neil JD, Owen TJ, Wood VH, Date KL, Valentine R, Chukwuma MB et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol 2008;89:2833-2842.
97. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984;310:207-211.
98. Yates JL, Camiolo SM. Dissection of DNA replication and enhancer activation function of Epstein-Barr virus nuclear antigen 1. Cancer Cells 1988;6:197-205.
99. Ambinder RF, Mullen MA, Chang YN, Hayward GS, Hayward SD. Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J Virol 1991;65:1466-1478.
100. Shah WA, Ambinder RF, Hayward GS, Hayward SD. Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions. J Virol 1992;66:3355-3362.
101. Goldsmith K, Bendell L, Frappier L. Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication. J Virol 1993;67:3418-3426.
102. Frappier L, Goldsmith K, Bendell L. Stabilization of the EBNA1 protein on the Epstein-Barr virus latent origin of DNA replication by a DNA looping mechanism. J Biol Chem 1994;269:1057-1062.
103. Bochkarev A, Barwell JA, Pfuetzner RA, Furey W Jr, Edwards AM, Frappier L. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1. Cell 1995;83:39-46.
104. Bochkarev A, Barwell JA, Pfuetzner RA, Bochkareva E, Frappier L, Edwards AM. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell 1996;84:791-800.
105. Summers H, Barwell JA, Pfuetzner RA, Edwards AM, Frappier L. Cooperative assembly of EBNA1 on the Epstein-Barr virus latent origin of replication. J Virol 1996;70:1228-1231.
106. Bochkarev A, Bochkareva E, Frappier L, Edwards AM. The 2.2A structure of a permanganate-sensitive DNA site bound by the Epstein-Barr virus origin binding protein, EBNA1. J Mol Biol 1998;284:1273-1278.
107. Heller M, Flemington E, Kieff E, Deininger P. Repeat arrays in cellular DNA related to the Epstein-Barr virus IR3 repeat. Mol Cell Biol 1985;5:457-465.
108. Heller M, Henderson A, Ripley S, Van Santen V, Kieff E. The IR3 repeat in Epstein-Barr virus DNA has homology to cell DNA, encodes part of a messenger RNA in EBV transformed cells but does not mediate integration of Epstein-Barr virus DNA. In: Prasad U et al. (eds) Nasopharyngeal Carcinoma: Current Concepts. University of Malaya: Kuala Lumpur, 1983, pp 177-202.
109. Heller M, van Santen V, Kieff E. Simple repeat sequence in Epstein-Barr virus DNA is transcribed in latent and productive infections. J Virol 1982;44:311-320.
110. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 2003;301:1371-1374.
111. Trivedi P, Masucci MG, Winberg G, Klein G. The Epstein-Barr-virusencoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. Int J Cancer 1991;48:794-800.
112. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-688.
113. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997;94:12616-12621.
114. Sharipo A, Imreh M, Leonchiks A, Imreh S, Masucci MG. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat Med 1998;4:939-944.
115. Dantuma NP, Heessen S, Lindsten K, Jellne M, Masucci MG. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci USA 2000;97:8381-8385.
116. Dantuma NP, Sharipo A, Masucci MG. Avoiding proteasomal processing: the case of EBNA1. Curr Top Microbiol Immunol 2002;269:23-36.
117. Fogg MH, Kaur A, Cho YG, Wang F. The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue. J Virol 2005;79:12681-12691.
118. Bashaw JM, Yates JL. Replication from oriP of Epstein-Barr virus requires exact spacing of two bound dimers of EBNA1 which bend DNA. J Virol 2001;75:10603-10611.
119. Hung SC, Kang MS, Kieff E. Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosomebinding domains, which can be replaced by high-mobility group-I or histone H1. Proc Natl Acad Sci USA 2001;98:1865-1870.
120. Middleton T, Sugden B. EBNA1 can link the enhancer element to the initiator element of the Epstein-Barr virus plasmid origin of DNA replication. J Virol 1992;66:489-495.
121. Middleton T, Sugden B. Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J Virol 1994;68:4067-4071.
122. Rawlins DR, Milman G, Hayward SD, Hayward GS. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985;42:859-868.
123. Yates JL, Camiolo SM, Bashaw JM. The minimal replicator of Epstein-Barr virus oriP. J Virol 2000;74:4512-4522.
124. Kitamura R, Sekimoto T, Ito S, Harada S, Yamagata H, Masai H et al. Nuclear import of Epstein-Barr virus nuclear antigen 1 mediated by NPI-1 (Importin alpha5) is up- and down-regulated by phosphorylation of the nuclear localization signal for which Lys379 and Arg380 are essential. J Virol 2006;80:1979-1991.
125. Kang MS, Hung SC, Kieff E. Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci USA 2001;98:15233-15238.
126. Yin Q, Flemington EK. siRNAs against the Epstein-Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBVdependent tumor cells. Virology 2006;346:385-393.
127. Nasimuzzaman M, Kuroda M, Dohno S, Yamamoto T, Iwatsuki K, Matsuzaki S et al. Eradication of Epstein-Bbarr virus episome and associated inhibition of infected tumor cell growth by adenovirus vectormediated transduction of dominant-negative EBNA1. Mol Ther 2005;11:578-590.
128. Ceccarelli DF, Frappier L. Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus. J Virol 2000;74:4939-4948.
129. Kirchmaier AL, Sugden B. Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. J Virol 1997;71:1766-1775.
130. Wu H, Kapoor P, Frappier L. Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J Virol 2002;76:2480-2490.
131. Lupton S, Levine AJ. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol 1985;5:2533-2542.
132. Jones CH, Hayward SD, Rawlins DR. Interaction of the lymphocytederived Epstein-Barr virus nuclear antigen EBNA-1 with its DNAbinding sites. J Virol 1989;63:101-110.
133. Hampar B, Tanaka A, Nonoyama M, Derge JG. Replication of the resident repressed Epstein-Barr virus genome during the early S phase (S-1 period) of nonproducer Raji cells. Proc Natl Acad Sci USA 1974;71:631-633.
134. Adams A. Replication of latent Epstein-Barr virus genomes in Raji cells. J Virol 1987;61:1743-1746.
135. Lindahl T, Adams A, Bjursell G, Bornkamm GW, Kaschka-Dierich C, Jehn U. Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J Mol Biol 1976;102:511-530.
136. Nonoyama M, Pagano JS. Replication of viral deoxyribonucleic acid and breakdown of cellular deoxyribonucleic acid in Epstein-Barr virus infection. J Virol 1972;9:714-716.
137. Yates JL, Guan N. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol 1991;65:483-488.
138. Sugden B, Warren N. Plasmid origin of replication of Epstein-Barr virus, oriP, does not limit replication in cis. Mol Biol Med 1988;5:85-94.
139. Kirchmaier AL, Sugden B. Plasmid maintenance of derivatives of oriP of Epstein-Barr virus. J Virol 1995;69:1280-1283.
140. Hudson GS, Gibson TJ, Barrell BG. The BamHI F region of the B95-8 Epstein-Barr virus genome. Virology 1985;147:99-109.
141. Reisman D, Sugden B. trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 1986;6:3838-3846.
142. Wysokenski DA, Yates JL. Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J Virol 1989;63:2657-2666.
143. Gahn TA, Sugden B. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J Virol 1995;69:2633-2636.
144. Puglielli MT, Woisetschlaeger M, Speck SH. OriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol 1996;70:5758-5768.
145. Aiyar A, Tyree C, Sugden B. The plasmid replicon of EBV consists of multiple cis-acting elements that facilitate DNA synthesis by the cell and a viral maintenance element. EMBO J 1998;17:6394-6403.
146. Shire K, Ceccarelli DF, Avolio-Hunter TM, Frappier L. EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance. J Virol 1999;73:2587-2595.
147. Fischer N, Kremmer E, Lautscham G, Mueller-Lantzsch N, Grasser FA. Epstein-Barr virus nuclear antigen 1 forms a complex with the nuclear transporter karyopherin alpha2. J Biol Chem 1997;272:3999-4005.
148. Holowaty MN, Zeghouf M, Wu H, Tellam J, Athanasopoulos V, Greenblatt J et al. Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem 2003;278:29987-29994.
149. Kim AL, Maher M, Hayman JB, Ozer J, Zerby D, Yates JL et al. An imperfect correlation between DNA replication activity of Epstein-Barr virus nuclear antigen 1 (EBNA1) and binding to the nuclear import receptor, Rch1/importin alpha. Virology 1997;239:340-351.
150. Van Scoy S, Watakabe I, Krainer AR, Hearing J. Human p32: a coactivator for Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent cycle DNA replication. Virology 2000;275:145-157.
151. Wang Y, Finan JE, Middeldorp JM, Hayward SD. P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus. Virology 1997;236:18-29.
152. Shire K, Kapoor P, Jiang K, Hing MN, Sivachandran N, Nguyen T et al. Regulation of the EBNA1 Epstein-Barr virus protein by serine phosphorylation and arginine methylation. J Virol 2006;80:5261-5272.
153. Sarkari F, Sanchez-Alcaraz T, Wang S, Holowaty MN, Sheng Y, Frappier L. EBNA1-mediated recruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication. PLoS Pathogen 2009;5:e1000624.
154. Sarkari F, Wang X, Nguyen T, Frappier L. The herpesvirus associated ubiquitin specific protease, USP7, is a negative regulator of PML proteins and PML nuclear bodies. PLoS One 2011;6:e16598.
155. Sivachandran N, Cao JY, Frappier L. Epstein-Barr virus nuclear antigen 1 Hijacks the host kinase CK2 to disrupt PML nuclear bodies. J Virol 2010;84:11113-11123.
156. Malik-Soni N, Frappier L. Proteomic profiling of EBNA1-host protein interactions in latent and lytic Epstein-Barr virus infections. J Virol 2012;86:6999-7002.
157. Murray RJ, Wang D, Young LS, Wang F, Rowe M, Kieff E et al. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol 1988;62:3747-3755.
158. Portal D, Zhao B, Calderwood MA, Sommermann T, Johannsen E, Kieff E. EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding. Proc Natl Acad Sci USA 2011;108:7808-7813.
159. Peng R, Moses SC, Tan J, Kremmer E, Ling PD. The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter. J Virol 2005;79:4492-4505.
160. Portal D, Zhou H, Zhao B, Kharchenko PV, Lowry E, Wong L et al. Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2. Proc Natl Acad Sci USA 2013;110:18537-18542.
161. Zhao B, Zou J, Wang H, Johannsen E, Peng CW, Quackenbush J et al. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci USA 2011;108:14902-14907.
162. Merkenschlager M, Odom DT. CTCF and cohesin: linking gene regulatory elements with their targets. Cell 2013;152:1285-1297.
163. Harada S, Kieff E. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol 1997;71:6611-6618.
164. Han I, Harada S, Weaver D, Xue Y, Lane W, Orstavik S et al. EBNA-LP associates with cellular proteins including DNA-PK and HA95. J Virol 2001;75:2475-2481.
165. Mannick JB, Tong X, Hemnes A, Kieff E. The Epstein-Barr virus nuclear antigen leader protein associates with hsp72/hsc73. J Virol 1995;69:8169-8172.
166. Portal D, Rosendorff A, Kieff E. Epstein-Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4. Proc Natl Acad Sci USA 2006;103:19278-19283.
167. Peng CW, Xue Y, Zhao B, Johannsen E, Kieff E, Harada S. Direct interactions between Epstein-Barr virus leader protein LP and the EBNA2 acidic domain underlie coordinate transcriptional regulation. Proc Natl Acad Sci USA 2004;101:1033-1038.
168. Henkel T, Ling PD, Hayward SD, Peterson MG. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 1994;265:92-95.
169. Tong X, Drapkin R, Yalamanchili R, Mosialos G, Kieff E. The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol 1995;15:4735-4744.
170. Tong X, Wang F, Thut CJ, Kieff E. The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein. J Virol 1995;69:585-588.
171. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of 'crippled' germinal center B cells from apoptosis by Epstein-Barr virus. Blood 2005;106:4339-4344.
172. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-399.
173. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-840.
174. Wang D, Liebowitz D, Kieff E. The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J Virol 1988;62:2337-2346.
175. Baichwal VR, Sugden B. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 1988;2:461-467.
176. Moorthy RK, Thorley-Lawson DA. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol 1993;67:1638-1646.
177. Hu LF, Chen F, Zheng X, Ernberg I, Cao SL, Christensson B et al. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993;8:1575-1583.
178. Kondo S, Wakisaka N, Schell MJ, Horikawa T, Sheen TS, Sato H et al. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer 2005;115:368-376.
179. Wakisaka N, Pagano JS. Epstein-Barr virus induces invasion and metastasis factors. Anticancer Res 2003;23:2133-2138.
180. Lo AK, Liu Y, Wang XH, Huang DP, Yuen PW, Wong YC et al. Alterations of biologic properties and gene expression in nasopharyngeal epithelial cells by the Epstein-Barr virus-encoded latent membrane protein 1. Lab Invest 2003;83:697-709.
181. Kim KR, Yoshizaki T, Miyamori H, Hasegawa K, Horikawa T, Furukawa M et al. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene 2000;19:1764-1771.
182. Nicholson LJ, Hopwood P, Johannessen I, Salisbury JR, Codd J, Thorley-Lawson D et al. Epstein-Barr virus latent membrane protein does not inhibit differentiation and induces tumorigenicity of human epithelial cells. Oncogene 1997;15:275-283.
183. Sheu LF, Chen A, Meng CL, Ho KC, Lee WH, Leu FJ et al. Enhanced malignant progression of nasopharyngeal carcinoma cells mediated by the expression of Epstein-Barr nuclear antigen 1 in vivo. J Pathol 1996;180:243-248.
184. Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995;69:4390-4398.
185. Niedobitek G, Fahraeus R, Herbst H, Latza U, Ferszt A, Klein G et al. The Epstein-Barr virus encoded membrane protein (LMP) induces phenotypic changes in epithelial cells. Virchows Arch B 1992;62:55-59.
186. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990;344:777-780.
187. Fahraeus R, Rymo L, Rhim JS, Klein G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 1990;345:447-449.
188. Carter KL, Cahir-McFarland E, Kieff E. Epstein-Barr virus-induced changes in B-lymphocyte gene expression. J Virol 2002;76:10427-10436.
189. Birkenbach M, Josefsen K, Yalamanchili R, Lenoir G, Kieff E. Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. J Virol 1993;67:2209-2220.
190. Birkenbach M, Liebowitz D, Wang F, Sample J, Kieff E. Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines. J Virol 1989;63:4079-4084.
191. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-1115.
192. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 1992;267:24157-24160.
193. Liebowitz D, Kieff E. Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin. J Virol 1989;63:4051-4054.
194. Martin JM, Veis D, Korsmeyer SJ, Sugden B. Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J Virol 1993;67:5269-5278.
195. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775-1782.
196. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent-induction of CD23, CD21, and ICAM-1. Leukemia 1993;7:104-112.
197. Rowe M, Peng-Pilon M, Huen DS, Hardy R, Croom-Carter D, Lundgren E et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 1994;68:5602-5612.
198. Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, Larson R et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988;62:4173-4184.
199. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990;64:2309-2318.
200. Zhang Q, Brooks L, Busson P, Wang F, Charron D, Kieff E et al. Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line. Eur J Immunol 1994;24:1467-1470.
201. Yang J, Deng X, Deng L, Gu H, Fan W, Cao Y. Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells. J Exp Clin Cancer Res 2004;23:495-506.
202. Liu HP, Chen CC, Wu CC, Huang YC, Liu SC, Liang Y et al. Epstein-Barr virus-encoded LMP1 interacts with FGD4 to activate Cdc42 and thereby promote migration of nasopharyngeal carcinoma cells. PLoS Pathogen 2012;8:e1002690.
203. Lo AK, Lo KW, Ko CW, Young LS, Dawson CW. Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells. J Pathol 2013;230:336-346.
204. Dutton A, Woodman CB, Chukwuma MB, Last JI, Wei W, Vockerodt M et al. Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 2007;109:2597-2603.
205. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 2008;27:421-433.
206. Yoshizaki T, Horikawa T, Qing-Chun R, Wakisaka N, Takeshita H, Sheen TS et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res 2001;7:1946-1951.
207. Chang MS, Kim DH, Roh JK, Middeldorp JM, Kim YS, Kim S et al. Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF-kappaB. J Virol 2013;87:10515-10523.
208. Yasui T, Luftig M, Soni V, Kieff E. Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. Proc Natl Acad Sci USA 2004;101:278-283.
209. Higuchi M, Izumi KM, Kieff E. Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc Natl Acad Sci USA 2001;98:4675-4680.
210. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-2224.
211. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 1996;93:11085-11090.
212. Ishida T, Mizushima S, Azuma S, Kobayashi N, Tojo T, Suzuki K et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996;271:28745-28748.
213. Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K et al. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc Natl Acad Sci USA 1996;93:14053-14058.
214. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996;13:2243-2254.
215. Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998;72:7900-7908.
216. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 1996;16:7098-7108.
217. Sylla BS, Hung SC, Davidson DM, Hatzivassiliou E, Malinin NL, Wallach D et al. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci USA 1998;95:10106-10111.
218. Luftig M, Prinarakis E, Yasui T, Tsichritzis T, Cahir-McFarland E, Inoue J et al. Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. Proc Natl Acad Sci USA 2003;100:15595-15600.
219. VanArsdale TL, VanArsdale SL, Force WR, Walter BN, Mosialos G, Kieff E et al. Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. Proc Natl Acad Sci USA 1997;94:2460-2465.
220. Miller CL, Lee JH, Kieff E, Burkhardt AL, Bolen JB, Longnecker R. Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction. Infect Agents Dis 1994;3:128-136.
221. Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007;110:3715-3721.
222. Ikeda M, Longnecker R. Cholesterol is critical for Epstein-Barr virus latent membrane protein 2A trafficking and protein stability. Virology 2007;360:461-468.
223. Katzman RB, Longnecker R. LMP2A does not require palmitoylation to localize to buoyant complexes or for function. J Virol 2004;78:10878-10887.
224. Anderson LJ, Longnecker R. EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway. J Gen Virol 2008;89:1563-1568.
225. Miller CL, Lee JH, Kieff E, Longnecker R. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA 1994;91:772-776.
226. Fukuda M, Kawaguchi Y. Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation. J Virol 2014;88:5189-5194.
227. Rochford R, Miller CL, Cannon MJ, Izumi KM, Kieff E, Longnecker R. In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2). Arch Virol 1997;142:707-720.
228. Speck P, Kline KA, Cheresh P, Longnecker R. Epstein-Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from that of wild-type virus. J Gen Virol 1999;80(Part 8):2193-2203.
229. Incrocci R, McCormack M, Swanson-Mungerson M. Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas. J Gen Virol 2013;94:1127-1133.
230. Portis T, Dyck P, Longnecker R. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003;102:4166-4178.
231. Fish K, Chen J, Longnecker R. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 2014;123:530-540.
232. Vrazo AC, Chauchard M, Raab-Traub N, Longnecker R. Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice. PLoS Pathogen 2012;8:e1002662.
233. Swanson-Mungerson M, Bultema R, Longnecker R. Epstein-Barr virus LMP2A imposes sensitivity to apoptosis. J Gen Virol 2010;91:2197-2202.
234. Bieging KT, Amick AC, Longnecker R. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Proc Natl Acad Sci USA 2009;106:17945-17950.
235. Bultema R, Longnecker R, Swanson-Mungerson M. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene 2009;28:1471-1476.
236. Ikeda M, Longnecker R. The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling. Virology 2009;385:183-191.
237. Anderson LJ, Longnecker R. Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. Blood 2009;113:108-116.
238. Swanson-Mungerson M, Longnecker R. Epstein-Barr virus latent membrane protein 2A and autoimmunity. Trends Immunol 2007;28:213-218.
239. Swanson-Mungerson MA, Caldwell RG, Bultema R, Longnecker R. Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen. J Virol 2005;79:7355-7362.
240. Sutkowski N, Chen G, Calderon G, Huber BT. Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen. J Virol 2004;78:7852-7860.
241. Allen MD, Young LS, Dawson CW. The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol 2005;79:1789-1802.
242. Chen F, Liu C, Lindvall C, Xu D, Ernberg I. Epstein-Barr virus latent membrane 2A (LMP2A) down-regulates telomerase reverse transcriptase (hTERT) in epithelial cell lines. Int J Cancer 2005;113:284-289.
243. Iwakiri D, Minamitani T, Samanta M. Epstein-Barr virus latent membrane protein 2A contributes to anoikis resistance through ERK activation. J Virol 2013;87:8227-8234.
244. Nakaya T, Kikuchi Y, Kunita A, Ishikawa S, Matsusaka K, Hino R et al. Enrichment of stem-like cell population comprises transformation ability of Epstein-Barr virus latent membrane protein 2A for nontransformed cells. Virus Res 2013;174:108-115.
245. Lin Z, Wan X, Jiang R, Deng L, Gao Y, Tang J et al. EBV-encoded LMP2A promotes EMT in nasopharyngeal carcinoma via MTA1 and mTOR signaling induction. J Virol 2014;88:11872-11885.
246. Fotheringham JA, Mazzucca S, Raab-Traub N. Epstein-Barr virus latent membrane protein-2A-induced DeltaNp63alpha expression is associated with impaired epithelial-cell differentiation. Oncogene 2010;29:4287-4296.
247. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 2009;69:2766-2774.
248. Pan YR, Vatsyayan J, Chang YS, Chang HY. Epstein-Barr virus latent membrane protein 2A upregulates UDP-glucose dehydrogenase gene expression via ERK and PI3K/Akt pathway. Cell Microbiol 2008;10:2447-2460.
249. Shah KM, Stewart SE, Wei W, Woodman CB, O'Neil JD, Dawson CW et al. The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene 2009;28:3903-3914.
250. Longnecker R, Kieff E. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol 1990;64:2319-2326.
251. Tomaszewski-Flick MJ, Rowe DT. Minimal protein domain requirements for the intracellular localization and self-aggregation of Epstein-Barr virus latent membrane protein 2. Virus Genes 2007;35:225-234.
252. Rovedo M, Longnecker R. Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn. J Virol 2008;82:8520-8528.
253. Longnecker R, Druker B, Roberts TM, Kieff E. An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 1991;65:3681-3692.
254. Scholle F, Longnecker R, Raab-Traub N. Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase. J Virol 1999;73:4767-4775.
255. Rechsteiner MP, Berger C, Zauner L, Sigrist JA, Weber M, Longnecker R et al. Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection. J Virol 2008;82:1739-1747.
256. Rovedo M, Longnecker R. Epstein-Barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol 2007;81:84-94.
257. Robertson ES, Lin J, Kieff E. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ (kappa). J Virol 1996;70:3068-3074.
258. Lin J, Johannsen E, Robertson E, Kieff E. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J Virol 2002;76:232-242.
259. Chen A, Divisconte M, Jiang X, Quink C, Wang F. Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J Virol 2005;79:4506-4509.
260. Maruo S, Johannsen E, Illanes D, Cooper A, Kieff E. Epstein-Barr virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth. J Virol 2003;77:10437-10447.
261. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, Takada K. Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci USA 2006;103:19500-19505.
262. Cooper A, Johannsen E, Maruo S, Cahir-McFarland E, Illanes D, Davidson D et al. EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth. J Virol 2003;77:999-1010.
263. Zhao B, Marshall DR, Sample CE. A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa. J Virol 1996;70:4228-4236.
264. Banerjee S, Lu J, Cai Q, Saha A, Jha HC, Dzeng RK et al. The EBV latent antigen 3C inhibits apoptosis through targeted regulation of interferon regulatory factors 4 and 8. PLoS Pathogen 2013;9:e1003314.
265. Zhao B, Sample CE. Epstein-Barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. J Virol 2000;74:5151-5160.
266. Harth-Hertle ML, Scholz BA, Erhard F, Glaser LV, Dolken L, Zimmer R et al. Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9. PLoS Pathogen 2013;9:e1003638.
267. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ. Epstein-Barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathogen 2009;5:e1000492.
268. Bazot Q, Deschamps T, Tafforeau L, Siouda M, Leblanc P, Harth-Hertle ML et al. Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1. Nucleic Acids Res 2014;42:9700-9716.
269. Maruo S, Wu Y, Ito T, Kanda T, Kieff ED, Takada K. Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth. Proc Natl Acad Sci USA 2009;106:4419-4424.
270. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci USA 2011;108:1919-1924.
271. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, Lang R et al. Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathogen 2009;5:e1000506.
272. Skalska L, White RE, Parker GA, Turro E, Sinclair AJ, Paschos K et al. Induction of p16 (INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathogen 2013;9:e1003187.
273. Lee S, Sakakibara S, Maruo S, Zhao B, Calderwood MA, Holthaus AM et al. Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1. J Virol 2009;83:12368-12377.
274. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 2012;122:1487-1502.
275. Allday MJ, Farrell PJ. Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 1994;68:3491-3498.
276. Zhao B, Mar. JC, Maruo S, Lee S, Gewurz BE, Johannsen E et al. Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci USA 2011;108:337-342.
277. Saha A, Robertson ES. Functional modulation of the metastatic suppressor Nm23-H1 by oncogenic viruses. FEBS Lett 2011;585:3174-3184.
278. Knight JS, Lan K, Subramanian C, Robertson ES. Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 2003;77:4261-4272.
279. Saha A, Halder S, Upadhyay SK, Lu J, Kumar P, Murakami M et al. Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathogen 2011;7:e1001275.
280. Saha A, Bamidele A, Murakami M, Robertson ES. EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol 2011;85:2079-2088.
281. Jha HC, A J MP, Saha A, Banerjee S, Lu J, Robertson ES. Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression. J Virol 2014;88:3776-3788.
282. Banerjee S, Lu J, Cai Q, Sun Z, Jha HC, Robertson ES. EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation. PLoS Pathogen 2014;10:e1004304.
283. Jha HC, Lu J, Saha A, Cai Q, Banerjee S, Prasad MA et al. EBNA3Cmediated regulation of aurora kinase B contributes to Epstein-Barr virusinduced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases. J Virol 2013;87:12121-12138.
284. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES. Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 2009;83:4652-4669.
285. Yi F, Saha A, Murakami M, Kumar P, Knight JS, Cai Q et al. Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 2009;388:236-247.
286. Knight JS, Sharma N, Robertson ES. Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci USA 2005;102:18562-18566.
287. Saha A, Lu J, Morizur L, Upadhyay SK, Aj MP, Robertson ES. E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathogen 2012;8:e1002573.
288. Piovan E, Tosello V, Indraccolo S, Cabrelle A, Baesso I, Trentin L et al. Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood 2005;105:931-939.
289. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ. Epigenetic repression of p16 (INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathogen 2010;6:e1000951.
290. McClellan MJ, Wood CD, Ojeniyi O, Cooper TJ, Kanhere A, Arvey A et al. Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming. PLoS Pathogen 2013;9:e1003636.
291. Jiang S, Willox B, Zhou H, Holthaus AM, Wang A, Shi TT et al. Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc Natl Acad Sci USA 2014;111:421-426.
292. Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ. BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res 2012;40:7233-7246.
293. Lerner MR, Andrews NC, Miller G, Steitz JA. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1981;78:805-809.
294. Rymo L. Identification of transcribed regions of Epstein-Barr virus DNA in Burkitt lymphoma-derived cells. J Virol 1979;32:8-18.
295. Iwakiri D. Epstein-Barr virus-encoded RNAs: key molecules in viral pathogenesis. Cancers (Basel) 2014;6:1615-1630.
296. Rosa MD, Gottlieb E, Lerner MR, Steitz JA. Striking similarities are exhibited by two small Epstein-Barr virus-encoded ribonucleic acids and the adenovirus-associated ribonucleic acids VAI and VAII. Mol Cell Biol 1981;1:785-796.
297. Gregorovic G, Bosshard R, Karstegl CE, White RE, Pattle S, Chiang AK et al. Cellular gene expression that correlates with EBER expression in Epstein-Barr Virus-infected lymphoblastoid cell lines. J Virol 2011;85:3535-3545.
298. Yajima M, Kanda T, Takada K. Critical role of Epstein-Barr Virus (EBV)-encoded RNA in efficient EBV-induced B-lymphocyte growth transformation. J Virol 2005;79:4298-4307.
299. Komano J, Maruo S, Kurozumi K, Oda T, Takada K. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 1999;73:9827-9831.
300. Houmani JL, Davis CI, Ruf IK. Growth-promoting properties of Epstein-Barr virus EBER-1 RNA correlate with ribosomal protein L22 binding. J Virol 2009;83:9844-9853.
301. Repellin CE, Tsimbouri PM, Philbey AW, Wilson JB. Lymphoid hyperplasia and lymphoma in transgenic mice expressing the small non-coding RNA, EBER1 of Epstein-Barr virus. PLoS One 2010;5:e9092.
302. Nanbo A, Takada K. The role of Epstein-Barr virus-encoded small RNAs (EBERs) in oncogenesis. Rev Med Virol 2002;12:321-326.
303. Kitagawa N, Goto M, Kurozumi K, Maruo S, Fukayama M, Naoe T et al. Epstein-Barr virus-encoded poly (A) (-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J 2000;19:6742-6750.
304. Iwakiri D, Eizuru Y, Tokunaga M, Takada K. Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res 2003;63:7062-7067.
305. Iwakiri D, Sheen TS, Chen JY, Huang DP, Takada K. Epstein-Barr virusencoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines. Oncogene 2005;24:1767-1773.
306. Yang L, Aozasa K, Oshimi K, Takada K. Epstein-Barr virus (EBV)-encoded RNA promotes growth of EBV-infected T cells through interleukin-9 induction. Cancer Res 2004;64:5332-5337.
307. Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J 2006;25:4207-4214.
308. Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBVinfected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009;206:2091-2099.
309. Toczyski DP, Steitz JA. The cellular RNA-binding protein EAP recognizes a conserved stem-loop in the Epstein-Barr virus small RNA EBER 1. Mol Cell Biol 1993;13:703-710.
310. Lee N, Pimienta G, Steitz JA. AUF1/hnRNP D is a novel protein partner of the EBER1 noncoding RNA of Epstein-Barr virus. RNA 2012;18:2073-2082.
311. Clarke PA, Sharp NA, Clemens MJ. Translational control by the Epstein-Barr virus small RNA EBER-1. Reversal of the double-stranded RNA-induced inhibition of protein synthesis in reticulocyte lysates. Eur J Biochem 1990;193:635-641.
312. McKenna SA, Lindhout DA, Shimoike T, Aitken CE, Puglisi JD. Viral dsRNA inhibitors prevent self-association and autophosphorylation of PKR. J Mol Biol 2007;372:103-113.
313. Katze MG, Wambach M, Wong ML, Garfinkel M, Meurs E, Chong K et al. Functional expression and RNA binding analysis of the interferoninduced, double-stranded RNA-activated, 68, 000-Mr protein kinase in a cell-free system. Mol Cell Biol 1991;11:5497-5505.
314. Sharp TV, Schwemmle M, Jeffrey I, Laing K, Mellor H, Proud CG et al. Comparative analysis of the regulation of the interferoninducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. Nucleic Acids Res 1993;21:4483-4490.
315. Fok V, Mitton-Fry RM, Grech A, Steitz JA. Multiple domains of EBER 1, an Epstein-Barr virus noncoding RNA, recruit human ribosomal protein L22. RNA 2006;12:872-882.
316. Elia A, Vyas J, Laing KG, Clemens MJ. Ribosomal protein L22 inhibits regulation of cellular activities by the Epstein-Barr virus small RNA EBER-1. Eur J Biochem 2004;271:1895-1905.
317. Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. Mda-5: An interferon-inducible putative RNA helicase with doublestranded RNA-dependent ATPase activity and melanoma growthsuppressive properties. Proc Natl Acad Sci USA 2002;99:637-642.
318. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathogen 2006;2:e23.
319. Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B. The microRNAs of Epstein-Barr Virus are expressed at dramatically differing levels among cell lines. Virology 2009;386:387-397.
320. Imig J, Motsch N, Zhu JY, Barth S, Okoniewski M, Reineke T et al. microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res 2011;39:1880-1893.
321. Marquitz AR, Mathur A, Chugh PE, Dittmer DP, Raab-Traub N. Expression profile of microRNAs in Epstein-Barr virus-infected AGS gastric carcinoma cells. J Virol 2014;88:1389-1393.
322. Kuzembayeva M, Hayes M, Sugden B. Multiple functions are mediated by the miRNAs of Epstein-Barr virus. Curr Opin Virol 2014;7C:61-65.
323. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 2008;68:1436-1442.
324. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009;5:376-385.
325. Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol 2012;189:3795-3799.
326. Feederle R, Haar J, Bernhardt K, Linnstaedt SD, Bannert H, Lips H et al. The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes. J Virol 2011;85:9801-9810.
327. Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathogen 2010;6:e1001063.
328. Wahl A, Linnstaedt SD, Esoda C, Krisko JF, Martinez-Torres F, Delecluse HJ et al. A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo. J Virol 2013;87:5437-5446.
329. Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A et al. Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene 2014;33:1258-1264.
330. Choi H, Lee H, Kim SR, Gho YS, Lee SK. Epstein-Barr virus-encoded microRNA BART15-3p promotes cell apoptosis partially by targeting BRUCE. J Virol 2013;87:8135-8144.
331. Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, White RE et al. An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 2010;8:510-522.
332. Kim SY, Song KA, Kieff E, Kang MS. Small molecule and peptidemediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization. Biochem Biophys Res Commun 2012;424:251-256.
333. Lee EK, Kim SY, Noh KW, Joo EH, Zhao B, Kieff E et al. Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome. Antiviral Res 2014;104:73-83.
334. Kang MS, Lee EK, Soni V, Lewis TA, Koehler AN, Srinivasan V et al. Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance. J Virol 2011;85:2859-2868.
335. Thompson S, Messick T, Schultz DC, Reichman M, Lieberman PM. Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1. J Biomol Screen 2010;15:1107-1115.
336. Li N, Thompson S, Schultz DC, Zhu W, Jiang H, Luo C et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One 2010;5:e10126.